中国医院用药评价与分析2019，Vol.19Issue(2)：147-149,152,4.DOI:10.14009/j.issn.1672-2124.2019.02.006
吸入用布地奈德混悬液联合吸入用复方异丙托溴铵溶液治疗慢性阻塞性肺疾病急性加重期的疗效观察
Observation on Efficacy of Budesonide Suspension for Inhalation Combined with Compound Ipratropium Bromide Solution for Inhalation in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
摘要
Abstract
OBJECTIVE: To probe into the efficacy of budesonide suspension for inhalation combined with compound ipratropium bromide solution for inhalation in treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). METHODS: 96 patients with AECOPD admitted into Zhongshan Xiaolan People's Hospital from May 2016 to Oct. 2018 were selected and divided into observation group and control group via random number table, with 48 cases in each group. The control group was given beclomethasone combined with compound ipratropium bromide solution for inhalation, while the observation group was given budesonide suspension for inhalation combined with compound ipratropium bromide solution for inhalation. Differences in clinical efficacy, indices of blood gas [arterial partial pressure of blood oxygen (PaO2), arterial partial pressure of blood carbon dioxide (PaCO2) and pH], indices of pulmonary function [forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and FEV1/FVC] and inflammation factors [serum interleukin-6 (IL-6), C-reactive protein (CRP), procalcitonin (PCT) and serum amyloid A (SAA) ] between two groups were compared. RESULTS: The total effective rate of observation group was 95.83％ (46/48), which was significantly higher than that of the control group (85.42％, 41/48), with statistically significant difference (P＜0.05). After treatment, the PaO2 and pH of both groups had been significantly improved, while the PaCO2 was significantly decreased; the PaO2 and pH of observation group were significantly higher than those of the control group, and the PaCO2 of observation group was significantly lower, with statistically significant differences (P＜0.05). After treatment, the FVC, FEV1 and FEV1/FVC of both groups were significantly increased, and those of observation group were significantly better than the control group, with statistically significant differences (P＜0.05). After treatment, the IL-6, CRP, PCT and SAA levels of both groups were significantly decreased, and those of observation group were significantly better than the control group, with statistically significant differences (P＜0.05). The incidence of adverse drug reactions of observation group was 4.17％ (2/48), which was significantly lower than that of the control group (16.67％, 8/48), with statistically significant difference (P＜0.05). CONCLUSIONS: The efficacy of budesonide suspension for inhalation combined with compound ipratropium bromide solution for inhalation in treatment of AECOPD is remarkable, which can effectively improve patients' pulmonary function and inflammation factor levels, with high safety and few adverse drug reactions.关键词
吸入用布地奈德混悬液/吸入用复方异丙托溴铵溶液/慢性阻塞性肺疾病急性加重期/疗效/安全性Key words
Budesonide suspension for inhalation/Compound ipratropium bromide solution/AECOPD/Efficacy/Safety分类
医药卫生引用本文复制引用
何添标,黎艳聪,李明标,袁健志..吸入用布地奈德混悬液联合吸入用复方异丙托溴铵溶液治疗慢性阻塞性肺疾病急性加重期的疗效观察[J].中国医院用药评价与分析,2019,19(2):147-149,152,4.基金项目
2018年中山市卫生和计划生育局医学科研计划项目(No.2018J195) （No.2018J195）
